|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Net Loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash share consideration, issued in acquisition of IPR&D | ||
| Amortization of beneficial conversion feature | ||
| Non-cash operating lease expense (benefit) | ||
| Depreciation expense | ||
| Share based compensation expense | ||
| Amortization of discounts on investments, net | ||
| Unrealized foreign currency transaction loss, net | ||
| Non-cash consideration relating to Pfizer Commercial Agreement | ||
| Non-cash write off of non-recourse promissory note | ||
| Changes in operating assets and liabilities: | ||
| Decrease (increase) in prepaid expenses and other current assets | ||
| (Increase) decrease in other receivable | ||
| Decrease (increase) in other non-current assets | ||
| Decrease in accounts payable | ||
| Increase in accrued expenses | ||
| Increase in nonrefundable research deposit | ||
| (Decrease) increase in other current liabilities | ||
| Decrease in related party payable | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities: | ||
| Purchase of property and equipment | ||
| Purchase of marketable securities | ||
| Sales and redemptions of marketable securities | ||
| Net cash used for investing activities | ||
| Cash flows from financing activities: | ||
| Proceeds from exercise of share options | ||
| Proceeds from issuance of ordinary shares upon initial public offering | ||
| Issuance costs | ||
| Ordinary Shares | ||
| Redeemable Convertible Preferred Shares | ||
| Proceeds from issuance of redeemable convertible preferred shares | ||
| Issuance of convertible notes | ||
| Debt issuance costs related to convertible notes | ||
| Net cash provided by financing activities | ||
| Effect of exchange rate changes on cash and cash equivalents | ||
| Net decrease in cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents, and restricted cash—beginning of period | ||
| Cash and cash equivalents, and restricted cash—ending of period | ||
| Supplemental disclosure of cash information | ||
| Cash paid for income taxes | ||
| Supplemental disclosure of non-cash financing and investing activities: | ||
| Right-of-use assets obtained in exchange for lease obligations | ||
| Ordinary shares received as consideration for non-recourse promissory note default | ||
| Issuance costs in accounts payable and other accrued liabilities | ||
| Beneficial conversion feature related to convertible notes | ||
| Purchase of property and equipment in accounts payable | ||
| Conversion of stock | ||
| Conversion of Preferred Shares | ||
| Conversion of Warrants | ||
| Cash and cash equivalents—end of period | ||
| Restricted cash—end of period |
Loading...
